MGI PHARMA, PARTNER WITHDRAW EUROPEAN DRUG APPLICATION

MGI Pharma Inc. and SuperGen Inc. have withdrawn their application for European marketing authorization for an experimental drug, the companies said Tuesday. The companies pulled the application after European regulators indicated that they would require additional clinical data on the use of Dacogen injections, which are used to treat blood disorders, including some forms of leukemia and solid tumors.

Twin Cities Business Journal (http://twincities.bizjournals.com/twincities/stories/2005/11/14/daily16.html)